Exome Asset Management LLC has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $146 Billion distributed in 56 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Eli Lilly & CO with a value of $9.26B, Ascendis Pharma A/S with a value of $6.55B, Bridge Bio Pharma, Inc. with a value of $5.37B, Structure Therapeutics Inc with a value of $5.27B, and Tg Therapeutics, Inc. with a value of $4.86B.

Examining the 13F form we can see an increase of $33.3B in the current position value, from $112B to 146B.

Exome Asset Management LLC is based out at New York, NY

Below you can find more details about Exome Asset Management LLC portfolio as well as his latest detailed transactions.

Portfolio value $146 Billion
Healthcare: $131 Billion

Stock Holdings Table Market Cap. of $200 Billions or more

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 56
  • Current Value $146 Billion
  • Prior Value $112 Billion
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 30 stocks
  • Additional Purchases 14 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 7 stocks
Track This Portfolio

Track Exome Asset Management LLC Portfolio

Follow Exome Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exome Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exome Asset Management LLC with notifications on news.